End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
853.4 INR | -0.55% | -1.65% | +29.88% |
15/05 | Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion | RE |
25/04 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 |
Sales 2024 | 22.83B 273M | Sales 2025 * | 25.67B 307M | Capitalization | 105B 1.25B |
---|---|---|---|---|---|
Net income 2024 | 4.71B 56.38M | Net income 2025 * | 5.47B 65.45M | EV / Sales 2024 | 4.04 x |
Net cash position 2024 | 3.02B 36.11M | Net cash position 2025 * | 2.5B 29.95M | EV / Sales 2025 * | 3.98 x |
P/E ratio 2024 |
20.2
x | P/E ratio 2025 * |
19.1
x | Employees | 1,824 |
Yield 2024 |
2.9% | Yield 2025 * |
2.58% | Free-Float | 15.72% |
Latest transcript on Glenmark Life Sciences Limited
1 day | -0.55% | ||
1 week | -1.65% | ||
Current month | +2.04% | ||
1 month | +3.91% | ||
3 months | +15.42% | ||
6 months | +34.64% | ||
Current year | +29.88% |
Managers | Title | Age | Since |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Director of Finance/CFO | - | 01/22/01 | |
Compliance Officer | - | 23/21/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 30/20/30 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11/18/11 |
Date | Price | Change | Volume |
---|---|---|---|
14/24/14 | 853.4 | -0.55% | 49,189 |
13/24/13 | 858.1 | -0.68% | 47,853 |
12/24/12 | 864 | -0.33% | 60,649 |
11/24/11 | 866.8 | -1.10% | 59,972 |
10/24/10 | 876.5 | +1.01% | 62,998 |
End-of-day quote NSE India S.E., June 14, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.88% | 1.25B | |
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- GLS Stock